Race Oncology Ltd (ASX:RAC, OTC:RAONF) invites shareholders and potential investors to attend a special online investor webinar to discuss the company’s recently lodged composition of matter patent application.
The session will feature executive chair Dr Pete Smith, managing director and CEO Dr Daniel Tillett and Professor Michael Kelso, Vice President of Research. They will provide insights into the composition of matter intellectual property discovery, outline the three patent applications submitted, and explain the significance of this development for both Race and investors.
Webinar details
Date: September 18, 2025
Time: 6pm to 7pm
Format: Online webinar
Click here to register: https://us02web.zoom.us/webinar/register/WN_3brVQ79-QNuuGy6pHaNvNg
Once registration is complete, participants will receive an email with instructions on how to access the session.
Investor lunch briefing in Hong Kong
Race will also hold an investor lunch briefing in Hong Kong on October 14, 2025, to present its clinical development strategy and highlight recent milestones.
Dr Pete Smith and Dr Daniel Tillett will update attendees on the company’s pipeline, including the opening of new clinical trial sites in Hong Kong. This development is regarded as a key step in advancing the global reach of Race’s cancer therapy program. The session will also provide investors with the opportunity to engage directly with management during a Q&A over lunch.
The event will be held in the Library Room at the Grand Hyatt Hotel, commencing at 12:30 pm Hong Kong time.
Places are limited and RSVPs are required by September 26, 2025.
RSVP by September 26, 2025 to: jane.lowe@irdepartment.com.au